DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 211 filers reported holding DENALI THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 4.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $33 | -93.6% | 1,500 | -94.0% | 0.00% | -88.9% |
| Q3 2023 | $512 | -19.5% | 24,800 | +15.1% | 0.01% | -18.2% |
| Q2 2023 | $636 | +28.2% | 21,540 | 0.0% | 0.01% | +10.0% |
| Q1 2023 | $496 | -14.2% | 21,540 | +3.7% | 0.01% | -16.7% |
| Q4 2022 | $578 | -99.9% | 20,780 | 0.0% | 0.01% | -14.3% |
| Q3 2022 | $638,000 | +17.1% | 20,780 | +12.3% | 0.01% | +27.3% |
| Q2 2022 | $545,000 | -8.4% | 18,511 | +0.0% | 0.01% | +10.0% |
| Q1 2022 | $595,000 | -21.3% | 18,510 | +9.2% | 0.01% | -23.1% |
| Q4 2021 | $756,000 | +894.7% | 16,943 | +1029.5% | 0.01% | +1200.0% |
| Q3 2021 | $76,000 | -35.6% | 1,500 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $118,000 | +37.2% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $86,000 | -48.8% | 1,500 | -25.0% | 0.00% | -50.0% |
| Q4 2020 | $168,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |